USDA Approves Fumonisin Test
Neogen announces Reveal® Q+ for Fumonisin
The USDA’s Grain Inspection, Packers and Stockyards Administration (GIPSA) has verified the performance of another of Neogen’s simple and accurate tests for fumonisin. GIPSA’s approval of Neogen’s Reveal® Q+ for Fumonisin enables the simple, fully quantitative lateral flow strip test to be used for official testing in the national grain inspection system.
After only 6 minutes, Reveal Q+ for Fumonisin delivers precise results ranging from 0.3 to 6 parts per million (ppm). Reveal Q+ test strips are read in Neogen’s AccuScan® III or AccuScan Pro lateral flow test readers to deliver the precision of more demanding test methods.
“Like our GIPSA-approved Reveal Q+ tests for aflatoxin, DON and zearalenone, Reveal Q+ for Fumonisin is the easiest test available for rapid, fully quantitative test results,” said Neogen’s Bridgett Wynkoop. “GIPSA’s approval verifies the test performs as designed, and allows regulators to add our improved test to the expanding list of Neogen’s products they can rely on to ensure the safety of our worldwide food and feed supply.”
Reveal Q+ for Fumonisin offers room temperature incubation of the test strip and storage of the test kit — eliminating the need for an incubator and refrigeration space. The test requires only minimal equipment to achieve precise results and uses a simple, low cost ethanol extraction process. Ethanol is the preferred extraction solvent of many major grain handlers.
Neogen’s AccuScan III and AccuScan Pro readers provide an easy method to objectively read, store, and analyze results from Neogen’s line of lateral flow tests. AccuScan provides a permanent result that can be incorporated into a company’s food safety plan, such as HACCP.
Fumonisin commonly infects corn and rice, hence the potential for fumonisin to be found in feed and foodstuffs is high. Fumonisin affects various animals differently, and is of special concern to horses and swine. It has been linked to esophageal cancer in humans. The EPA classifies fumonisin as a category II-B carcinogen.
